🇺🇸 FDA
Patent

US 9302015

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

granted A61KA61K2039/505A61K31/537

Quick answer

US patent 9302015 (Anti-PRLR antibodies and methods for killing PRLR-expressing cells) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
57
CPC classes
A61K, A61K2039/505, A61K31/537, A61K47/68031, A61K47/68033